Esophageal cancer is the seventh most common malignancy worldwide, with over 470 000
new cases diagnosed each year. Two distinct histological subtypes predominate, and …

Recent single-arm studies involving neoadjuvant camrelizumab, a PD-1 inhibitor, plus
chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (LA …

Esophageal cancer (EC) ranks among the most prevalent malignant tumors affecting the
digestive tract. Esophageal squamous cell carcinoma (ESCC) stands as the prevailing …

Neoadjuvant chemoimmunotherapy (NACI) has shown promise in the treatment of
resectable esophageal squamous cell carcinoma (ESCC). The microbiomes of patients can …

Abstract Background A Phase II study was undertaken to evaluate the safety and efficacy of
the neoadjuvant socazolimab, a novel PD-L1 inhibitor, in combination with nab-paclitaxel …

Background Esophageal squamous cell carcinoma (ESCC) is the most common type of
esophageal cancer in China. The use of neoadjuvant immunotherapy for the treatment of …

In this phase II study, 47 patients with locally advanced, resectable esophageal squamous
cell carcinoma (ESCC) received three cycles of pembrolizumab plus chemotherapy …

Simple Summary The management of locally advanced esophageal cancer poses
considerable challenges and current strategies have significant risks. Moreover, despite …

Tertiary lymphoid structures (TLSs) were associated with survival in esophageal squamous
cell carcinoma (ESCC) undergoing surgery alone (SA). However, their clinical relevance in …

Esophageal squamous cell carcinoma (ESCC) is a common malignancy worldwide and
often diagnosed at advanced stages with poor prognosis. Combination of radiotherapy and …